Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

BACKGROUND: While lenalidomide (LEN) shows high efficacy in myelodysplastic syndromes (MDS) with del[5q], responses can be also seen in patients presenting without del[5q]. We hypothesized that improved detection of chromosomal abnormalities with new karyotyping tools may better predict response to...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Sugimoto, Yuka, Sekeres, Mikkael A, Makishima, Hideki, Traina, Fabiola, Visconte, Valeria, Jankowska, Anna, Jerez, Andres, Szpurka, Hadrian, O'Keefe, Christine L, Guinta, Kathryn, Afable, Manuel, Tiu, Ramon, McGraw, Kathy L, List, Alan F, Maciejewski, Jaroslaw
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2012
Ämnen:
Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3323440/
https://ncbi.nlm.nih.gov/pubmed/22390313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-5-4
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk